The Impact of Adjuvant Radiotherapy Combined With Targeted or Immunotherapy on the Heart in Breast Cancer
Thoracic Cancer · 2026-05 · 17 (10)
DOI: 10.1111/1759-7714.70298 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 24.05.2026. Verfasst von Dongmin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Cli…. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy, Cardiotoxicity, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Key Medical Discipline Construction Project.
Abstract (Originalsprache)
With the increasing adoption of combination therapies involving targeted therapy, immunotherapy, and radiotherapy in breast cancer treatment, the potential cardiotoxicity risks have emerged as a major clinical concern. This article reviews key clinical trial evidence from recent years, including studies published up to March 2025, focusing on the short‐term and long‐term cardiovascular impacts of combination therapies, aiming to provide clinically relevant guidance for decision‐making. Current clinical studies indicate relatively low rates of acute cardiac adverse events during the treatment period. However, long‐term follow‐up data reveal that patients receiving high‐dose radiotherapy (cardiac radiation dose ≥ 25 Gy) show a significantly increased 10‐year risk of cardiovascular events. Emerging evidence suggests that cardiotoxicity exhibits delayed onset characteristics and significant interindividual variability. Therefore, future research should prioritize long‐term cardiac monitoring in combined treatment regimens and actively explore effective strategies to mitigate cardiotoxicity risks. Proposed approaches include establishing comprehensive dynamic monitoring systems integrating radiomics and biomarkers, optimizing radiotherapy dosing to minimize cardiac damage, and developing myocardial protective agents, ultimately achieving optimal balance between treatment efficacy and patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention…
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Sciences, China Three Gorges University, Yichang, China.
- Department of Anesthesia, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Ther…
ORCID-Profile: Dongmin Liu
Förderung
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Liu, D., Yang, Y., Chen, T., Han, H., Yuan, Y., & Xu, L. (2026). The Impact of Adjuvant Radiotherapy Combined With Targeted or Immunotherapy on the Heart in Breast Cancer. Thoracic Cancer, 17(10). https://doi.org/10.1111/1759-7714.70298
Vancouver
Liu D, Yang Y, Chen T, Han H, Yuan Y, Xu L. The Impact of Adjuvant Radiotherapy Combined With Targeted or Immunotherapy on the Heart in Breast Cancer. Thoracic Cancer. 2026;17(10). doi:10.1111/1759-7714.70298
BibTeX
@article{Liu2026,
author = {Liu, Dongmin and Yang, Yanling and Chen, Tingting and Han, Haonan and Yuan, Yajing and Xu, Liming},
title = {The Impact of Adjuvant Radiotherapy Combined With Targeted or Immunotherapy on the Heart in Breast Cancer},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {10},
doi = {10.1111/1759-7714.70298}
}
EUVIMED